Biodesix, Inc. (NASDAQ:BDSX) Shares Bought by Perkins Capital Management Inc.

Perkins Capital Management Inc. lifted its position in shares of Biodesix, Inc. (NASDAQ:BDSX) by 74.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 724,782 shares of the company’s stock after acquiring an additional 310,000 shares during the quarter. Biodesix accounts for approximately 1.2% of Perkins Capital Management Inc.’s portfolio, making the stock its 27th largest holding. Perkins Capital Management Inc. owned about 0.50% of Biodesix worth $1,290,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. AIGH Capital Management LLC raised its stake in shares of Biodesix by 74.0% during the 2nd quarter. AIGH Capital Management LLC now owns 5,779,812 shares of the company’s stock worth $8,843,000 after buying an additional 2,458,727 shares in the last quarter. Perceptive Advisors LLC purchased a new position in Biodesix in the second quarter worth $3,326,000. Farallon Capital Management LLC acquired a new stake in Biodesix in the second quarter valued at $2,874,000. Opaleye Management Inc. grew its stake in shares of Biodesix by 7.7% during the 1st quarter. Opaleye Management Inc. now owns 534,657 shares of the company’s stock worth $765,000 after purchasing an additional 38,157 shares during the period. Finally, CVI Holdings LLC purchased a new position in shares of Biodesix in the 2nd quarter valued at about $59,000. 20.96% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Biodesix news, Director Matthew Strobeck purchased 40,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The shares were acquired at an average price of $1.40 per share, for a total transaction of $56,000.00. Following the completion of the purchase, the director now owns 2,606,879 shares in the company, valued at $3,649,630.60. The trade was a 0.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Matthew Strobeck bought 40,000 shares of Biodesix stock in a transaction on Tuesday, November 5th. The shares were bought at an average price of $1.40 per share, with a total value of $56,000.00. Following the acquisition, the director now directly owns 2,606,879 shares in the company, valued at approximately $3,649,630.60. This represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman John Patience purchased 75,000 shares of the stock in a transaction dated Tuesday, November 5th. The stock was purchased at an average price of $1.38 per share, with a total value of $103,500.00. Following the completion of the acquisition, the chairman now directly owns 2,153,298 shares in the company, valued at approximately $2,971,551.24. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here. Insiders sold 5,359 shares of company stock worth $8,533 over the last ninety days. Corporate insiders own 69.20% of the company’s stock.

Biodesix Stock Performance

Biodesix stock opened at $1.33 on Thursday. The firm has a market capitalization of $193.47 million, a PE ratio of -3.41 and a beta of 1.22. Biodesix, Inc. has a one year low of $1.15 and a one year high of $2.21. The stock’s 50 day moving average price is $1.70 and its 200 day moving average price is $1.61. The company has a debt-to-equity ratio of 0.99, a quick ratio of 3.28 and a current ratio of 3.28.

Biodesix (NASDAQ:BDSX) last posted its earnings results on Friday, November 1st. The company reported ($0.07) EPS for the quarter, hitting analysts’ consensus estimates of ($0.07). Biodesix had a negative net margin of 66.84% and a negative return on equity of 369.89%. The business had revenue of $18.15 million for the quarter, compared to analysts’ expectations of $18.45 million. During the same period in the previous year, the company posted ($0.12) earnings per share. As a group, sell-side analysts expect that Biodesix, Inc. will post -0.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

BDSX has been the subject of a number of research reports. Craig Hallum began coverage on shares of Biodesix in a research report on Friday, July 26th. They set a “buy” rating and a $3.00 price target for the company. Scotiabank started coverage on Biodesix in a research note on Monday, September 16th. They set a “sector outperform” rating and a $3.00 price target for the company. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $3.06.

Biodesix Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.